文献速递外周动脉疾病

经皮跨壁动脉旁路术在常规实践中的2年经验

Percutaneous transmural arterial bypass in routine practice: Our 2-year experience.
PubMed 文献 · J Vasc Surg · 2026-06-10

该研究回顾性分析了44例患者共49例经皮跨壁动脉旁路术(PTAB)的疗效,技术成功率100%,但1年一期通畅率仅47.6%、一期辅助通畅率71.4%,均低于DETOUR试验报告的水平;18个月时仅1例保持一期通畅,提示需密切术后监测和及时再干预。

要点

  • 常规实践中PTAB的1年一期通畅率(47.6%)低于DETOUR试验报告的81%和72.1%。
  • 所有患者术后均接受口服抗血小板联合抗凝治疗,技术成功率达100%。
  • 16例发生支架闭塞,20例需再干预,2例因支架闭塞行大截肢。

核心结论

  • 本中心PTAB的一期通畅率和一期辅助通畅率低于DETOUR试验报告水平。
  • 接受PTAB的患者需要密切的术后监测和及时的再干预。

研究设计与样本

  • 回顾性分析2023年8月至2025年12月在本医疗系统内接受PTAB的患者。
  • 共44例患者接受49例PTAB,男性占61.4%,平均年龄71.0±7.3岁。
  • 主要终点为术后1、3、6、12、18、24个月的一期、一期辅助和二期通畅率。

主要发现

  • 治疗股浅动脉闭塞平均长度为303.0±125.1 mm,技术成功率为100%。
  • 平均随访312天(范围6-788天),1、3、6、12个月一期通畅率分别为97.8%、84.6%、60.6%、47.6%。
  • 对应时间点一期辅助通畅率分别为100%、87.2%、69.7%、71.4%,二期通畅率分别为100%、100%、90.9%、90.5%。
  • 18个月时(n=12)仅1例保持一期通畅(8.3%),一期辅助通畅率和二期通畅率分别为41.7%和83.3%。
  • 共发生16例支架闭塞,20例需再干预,2例因支架闭塞行大截肢。

关键数值与推荐

  • DETOUR1试验报告1年一期通畅率81±4%、一期辅助通畅率82±4%、二期通畅率90±3%。
  • DETOUR2试验报告1年一期通畅率72.1%、一期辅助通畅率77.7%、二期通畅率89.0%。

临床怎么用

  • PTAB术后应进行密切的通畅性监测,以便及时发现支架闭塞或狭窄。
  • 对发现的血流动力学异常或症状复发应及时再干预,以维持通畅并避免大截肢。

局限性

  • 本研究为单中心回顾性分析,样本量较小(44例患者、49例PTAB)。
  • 18个月和24个月随访病例数极少(分别为12例和3例),远期通畅率数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Percutaneous transmural arterial bypass (PTAB) (Endologix) integrates principles of open surgical bypass with minimally invasive endovascular techniques to treat long-segment occlusions of the superficial femoral artery and popliteal artery. DETOUR1 (DETOUR I Clinical Study for Percutaneous Femoropopliteal Bypass) demonstrated favorable 1-year patency outcomes, with a primary patency rate (PPR), primary-assisted patency rate (PAPR), and secondary patency rate (SPR) of 81 ± 4%, 82 ± 4%, and 90 ± 3%, respectively. Similarly, the following DETOUR2 trial reported acceptable 1-year patency, with a PPR of 72.1%, PAPR of 77.7%, and SPR of 89.0%. However, outcomes of PTAB outside of the DETOUR clinical trials remain limited. METHODS: A retrospective analysis of patients who underwent PTAB within our health care system was conducted from August 2023 to December 2025. Collected variables included patient demographics, perioperative details, and postoperative outcomes. Primary end points were PPR, PAPR, and SPR assessed at 1, 3, 6, 12, 18, and 24 months. RESULTS: A total of 49 PTABs were performed in 44 patients (61.4 % male; mean age, 71.0 ± 7.3 years). The mean treated superficial femoral artery occlusion length was 303.0 ± 125.1 mm. Technical success was achieved in 100% of cases, and all patients were discharged on combined oral antiplatelet and anticoagulant therapy. The mean follow-up duration was 312 days (range, 6-788 days). PPRs at 1, 3, 6, and 12 months were 97.8%, 84.6%, 60.6%, and 47.6%, respectively. Corresponding PAPRs were 100%, 87.2%, 69.7%, 71.4%, respectively, and SPRs were 100%, 100%, 90.9%, and 90.5% at the same intervals. At 18 months (n = 12), only one patient had primary patency (8.3%); the PAPRs and SPRs were 41.7% and 83.3%, respectively. Only three patients were present for the 24-month follow-up, all of whom had required intervention to maintain patency. Overall, 16 stent occlusions occurred, 20 patients required intervention, and 2 patients underwent major amputation secondary to stent occlusion. CONCLUSIONS: The PTAB device in our experience was associated with lower PPRs and PAPRs than those reported in the DETOUR trials. These findings underscore the need for close postprocedural surveillance and timely reintervention in patients who undergo PTAB.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bruggeman M, Tsouknidas I, Feeney K, et al. Percutaneous transmural arterial bypass in routine practice: Our 2-year experience. J Vasc Surg. 2026. PMID: 42270053. doi:10.1016/j.jvs.2026.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。